Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Background Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human papillomavirus (HPV). Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1) pathway are effective against unresectable...

Full description

Bibliographic Details
Main Authors: Bin Li, Jun Li, Tian Chen, Uwe M Martens, Lazar Vujanovic, Rom Leidner, Robert L Ferris, William Sharfman, Chrisann Kyi, Suzanne L Topalian, Janis M Taube, Christine H Chung, William C Spanos, Anthony Gonçalves, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Julie E Stein, Adam Barrows
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002568.full

Internet

https://jitc.bmj.com/content/9/6/e002568.full

Similar Items